SCICLONE PHARMACEUTICALS INC - FORM 10-K - EX-32.1 - SECTION 1350 CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER - March 16, 2010

Attached files

file filename
10-K - FORM 10-K - SCICLONE PHARMACEUTICALS INCd10k.htm
EX-32.2 - SECTION 1350 CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER - SCICLONE PHARMACEUTICALS INCdex322.htm
EX-31.1 - RULE 13A-14(A) CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER - SCICLONE PHARMACEUTICALS INCdex311.htm
EX-21.1 - SUBSIDIARIES OF REGISTRANT - SCICLONE PHARMACEUTICALS INCdex211.htm
EX-31.2 - RULE 13A-14(A) CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER - SCICLONE PHARMACEUTICALS INCdex312.htm
EX-23.1 - CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM - SCICLONE PHARMACEUTICALS INCdex231.htm
EX-10.61 - DESCRIPTION OF EXECUTIVE INCENTIVE PLAN - SCICLONE PHARMACEUTICALS INCdex1061.htm

EXHIBIT 32.1

SECTION 1350 CERTIFICATION OF CHIEF EXECUTIVE OFFICER

I, Friedhelm Blobel, Chief Executive Officer of SciClone Pharmaceuticals, Inc. (the “Registrant”), do hereby certify in accordance with 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, based on my knowledge:

 

(1) the Annual Report on Form 10-K of the Registrant, to which this certification is attached as an exhibit (the “Report”), fully complies with the requirements of section 13(a) of the Securities Exchange Act of 1934 (15 U.S.C. 78m); and

 

(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant.

 

Date: March 16, 2010     /S/    FRIEDHELM BLOBEL, PH.D.        
   

Friedhelm Blobel, Ph.D.

Chief Executive Officer

A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to SciClone Pharmaceuticals, Inc. and will be retained by SciClone Pharmaceuticals, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.

SCICLONE PHARMACEUTICALS INC Reports